AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TAT GIDA SANAYİ A.Ş.

Share Issue/Capital Change Aug 14, 2024

9121_rns_2024-08-14_99584fe3-61c7-46ef-b539-49e7ee97e1d7.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

Summary Info CMB Application Related to Capital Increase
Update Notification Flag Yes
Correction Notification Flag No
Postponed Notification Flag No
Board Decision Date 09.08.2024
Authorized Capital (TL) 250.000.000
Paid-in Capital (TL) 136.000.000
Target Capital (TL) 244.800.000

Rights Issue (Via Preemptive Right)

Share Group Info Paid-in Capital (TL) Preemptive Rights Amount (TL) Preemptive Rights Rate (%) Preemptive Rights Price Share Group Issued New Shares'' ISIN Form Preemptive Rights ISIN Code Unused Rights Amount (TL) Amount of Shares Cancelled (TL)
TATGD, TRATATKS91A5 136.000.000 108.800.000,000 80,00000 1,00 TATGD, TRATATKS91A5 Registered
Paid-in Capital (TL) Preemptive Rights Amount (TL) Preemptive Rights Rate (%) Unused Rights Amount (TL) Amount of Shares Cancelled (TL)
TOTAL 136.000.000 108.800.000,000 80,00000
Currency Unit TRY

Other Aspects To Be Notified

Capital Market Board Application Date 14.08.2024
Property of Increased Capital Shares Dematerialized Share

Additional Explanations

An application was made to the Capital Markets Board today (14.08.2024) for the approval of the prospectus prepared for the issuance and public offering of shares with a nominal value of TRY 108.800.000 due to the increase in our Company's issued capital from TRY 136.000.000 to TRY 244.800.000 within the registered capital ceiling of TRY 250.000.000, with TRY 108.800.000 in cash.

This statement was translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.

Talk to a Data Expert

Have a question? We'll get back to you promptly.